Journal: Foods

Article Title: Sea Buckthorn Pericarp Flavonoids Improve Diet-Induced Hyperlipidemia via Coordinated Modulation of Hepatic Lipid Metabolism and Gut Microbiota

doi: 10.3390/foods15061049

Figure Lengend Snippet: TFSP modulates the expression of ACC, FAS, CPT-1α, PPARα and ATGL proteins in the livers of HFD mice. n = 6 per group. Data are presented as mean ± SD. Different letters above bars indicate statistically significant differences ( p < 0.05) by one-way ANOVA followed by LSD post hoc test.

Article Snippet: Peroxisome proliferator-activated receptor alpha (PPARα) primary antibody (Cat. No. A00600-2), carnitine palmitoyltransferase-1 alpha (CPT-1α) primary antibody (Cat. No. A00917-3), acetyl-CoA carboxylase (ACC) primary antibody (Cat. No. M01802-2), fatty acid synthase (FAS) primary antibody (Cat. No. BA0484), adipose triglyceride lipase (ATGL) primary antibody (Cat. No. A01800-1), and GAPDH primary antibody (Cat. No. BM1623) were obtained from BOSTER Biological Technology Co., Ltd. (Wuhan, China).

Techniques: Expressing

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Validation of CD59 knock-down in DLBCL cell lines. ( A ) Representative immunoblots showing CD59 protein levels in SU-DHL-4 and U2932 cell lines transfected with three distinct CD59-shRNA constructs or control vectors. β-actin served as the loading control. ( B and C ) Quantitative analysis of relative CD59 mRNA (by qRT-PCR) and protein (by densitometry) levels in SU-DHL-4 (B) and U2932 (C) cells. Data are presented as mean ± SD and normalized to the blank control group.** p < 0.01; *** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Biomarker Discovery, Knockdown, Western Blot, Transfection, shRNA, Construct, Control, Quantitative RT-PCR

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: CD59 knock-down promotes G0/G1 cell-cycle arrest in SU-DHL-4 and U2932 cells. ( A and B ) Representative propidium-iodide histograms for wild-type and shCD59 transduced SU-DHL-4 (A) and U2932 (B) cells under indicated treatments. ( C ) Bar graph summarizing the proportions of cells in G0/G1, S, and G2/M phases for SU-DHL-4 (left) and U2932 (right) cell lines. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Knockdown

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: CD59 knock-down enhances drug-induced apoptosis in DLBCL cell lines. (A-B) Representative Annexin V-PE/7-AAD flow-cytometry plots for wild-type and shCD59 transduced SU-DHL-4 ( A ) and U2932 ( B ) cells under the indicated treatments. ( C ) Bar-graph summarizing the percentage of early + late apoptotic cells. ns p > 0.05, * p < 0.05, ** p < 0.01*** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Knockdown, Flow Cytometry

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Representative immunohistochemical staining of CD59 in DLBCL tissue specimens. Images show CD59 expression at both 200× (upper panels) and 400× (lower panels) magnification. Representative fields were classified as negative, weakly positive, and positive for CD59 expression. Scale bars: 50 μm (200×) and 20 μm (400×)

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Progression-free (PFS) and overall survival (OS) analyses based on CD59 expression status in DLBCL. (A and B) Kaplan-Meier curves representing PFS ( A ) and OS ( B ) for 36 CHOP-treated patients stratified by CD59 immunostaining. (C and D) Kaplan-Meier curves representing PFS ( C ) and OS ( D ) for 67 patients who received R-CHOP. (E and F) Kaplan-Meier curves representing PFS ( E ) and OS ( F ) for entire cohort according to CD59 expression. P-values were calculated with the log-rank test

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Expressing, Immunostaining

Journal: Journal of xenobiotics

Article Title: Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines.

doi: 10.3390/jox14030073

Figure Lengend Snippet: Figure 1. Mutant cell enrichment by separation with anti-CD59 microbeads and paramagnetic separator.

Article Snippet: Anti-mouse PE-conjugated CD59 antibody (Clone REA287, Lot no. 5230105732), anti-human PE-conjugated CD59 antibody (Clone REA496, Lot no. 1322120604), lyophilized anti-PE MicroBeads (Lot no. 5181221156), LS columns (Lot no. 5180927085), and a QuadroMACS separator were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

Techniques: Mutagenesis

Journal: Journal of xenobiotics

Article Title: Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines.

doi: 10.3390/jox14030073

Figure Lengend Snippet: Figure 8. PIG-A gating strategy: (a) gating strategies for separating GPI(−) (lower left region) and GPI(+) (lower right region) of TK6 cell line; (b) gating strategies for separating GPI(−) (lower left region) and GPI(+) (lower right region) of Hepa1c1c7 cell line. PIG-A gene mutated cells were not stained with anti-CD59 antibodies and had no PE signal that was conjugated with antibodies.

Article Snippet: Anti-mouse PE-conjugated CD59 antibody (Clone REA287, Lot no. 5230105732), anti-human PE-conjugated CD59 antibody (Clone REA496, Lot no. 1322120604), lyophilized anti-PE MicroBeads (Lot no. 5181221156), LS columns (Lot no. 5180927085), and a QuadroMACS separator were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

Techniques: Staining

Journal: Molecular Medicine Reports

Article Title: The effect of anti-HLA class I antibodies on the immunological properties of human glomerular endothelial cells and their modification by mTOR inhibition or GCN2 kinase activation

doi: 10.3892/mmr.2021.11994

Figure Lengend Snippet: Effect of anti-HLAI on ICAM-1, HLA-DR, CD46 and CD59, and the impact of halofuginone or everolimus treatment. (A) Representative experiment for each of the evaluated factors. (B) Cumulative results are presented. Anti-HLAI antibodies upregulated ICAM-1, HLA-DR, CD46 and CD59. Halofuginone or everolimus treatment decreased ICAM-1. Data are presented as the mean ± SEM. *P<0.05 vs. control cells, # P<0.05 vs. anti-HLAI-treated cells, ^ P<0.05 vs. anti-HLAI-treated cells administered halofuginone, + P<0.05 vs. anti-HLAI-treated cells administered everolimus and $ P<0.05 vs. anti-HLAI-treated cells with halofuginone and everolimus. HLAI, human leukocyte antigen class I; ICAM-1, intracellular adhesion molecule-1; Hal, halofuginone; Ever, everolimus; Ctrl, control.

Article Snippet: Blots were incubated at 4°C for 16 h with the primary antibodies specific against activated cleaved caspase-3 (cleaved caspase-3, 1:1,000, cat. no ab13847, Abcam), focal adhesion kinase (FAK, 1:100, cat. no sc-271126, Santa Cruz Biotechnology, Inc.), phosphorylated at Tyr397 FAK (p-FAK, 1:1,000, cat. no 8556, Cell Signaling Technology, Inc.), mTOR (1:100, cat. no sc-517464, Santa Cruz Biotechnology, Inc.), phosphorylated at Ser2448 mTOR (p-mTOR, 1:100, cat. no sc-293133, Santa Cruz Biotechnology, Inc.), p70S6 kinase (p70S6K, 1:100, cat. no sc-8418, Santa Cruz Biotechnology, Inc.), phosphorylated at Thr389 p70S6K (p-p70S6K, 1:1,000, cat. no 9234, Cell Signaling Technology), protein kinase B (Akt, 1:100, cat. no sc-5298, Santa Cruz Biotechnology, Inc.), phosphorylated at Ser474 Akt (p-Akt, 1:1,000, cat. no 4060, Cell Signaling Technology, Inc.), GCN2 kinase (GCN2K, 1:100, cat. no sc-374609, Santa Cruz Biotechnology, Inc.), phosphorylated at Thr899 GCN2K (p-GCN2K, 1:1,000, cat. no ab75836; Abcam), eIF2α (1:100, cat. no sc-133132, Cell Signaling Technology, Inc.), phosphorylated at Ser51 eIF2α (p-eIF2a, 1:1,000, cat. no 9721, Cell Signaling Technology, Inc.), intercellular adhesion molecule 1 (ICAM-1, 1:1,000, cat. no 4915; Cell Signaling Technology), HLA-DR (Ultra-LEAFTM Purified anti-human HLA-DR Antibody, cat. no 307648, Biolegend), CD46 (1:1,000, cat. no CSB-PA923298, Cusabio), CD59 (1:1,000, cat. no CSB-PA004947YA01HU, Cusabio), and β-actin (1:5,000, cat no. 4967, Cell Signaling Technology, Inc.).

Techniques: Control

Journal:

Article Title: Regulated complement deposition on the surface of human endothelial cells: Effect of tobacco smoke and shear stress

doi: 10.1016/j.thromres.2007.11.005

Figure Lengend Snippet: Changes in cell surface expression of complement regulators (Mean ± S.D.), CR1 (CD35) (n = 3), DAF (CD55) (n = 4), and Protectin (CD59) (n = 4) in response to BMEC exposure to TS (0.03 puffs/ml), chemical (LPS at 1 μg/ml or INF-γ at 100 U/ml), or mechanical shear stress (18 dyne/cm2). Results were normalized to baseline CD35, CD59 and Cd59 expression observed on untreated BMEC monolayers. The data were analyzed by single factor ANOVA. (*) Denotes a statistically significant increase (P<0.05).

Article Snippet: Murine monoclonal anti-human CD35, CD55, and CD59 antibodies were obtained from Ancell Corporation (Bayport, MN), and used at concentrations of 1 μg/ml, 10 μg/ml, and 5 μg/ml, respectively.

Techniques: Expressing